RxDoctor Payments DataLook up a doctor →

Eric Achtyes, MD

Psychiatry · Grand Rapids, MINPI 1780665976

Payments from drug & device makers

$705,158in general payments, 2019–2025

Across 509 payments — averaging $1385.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$204K
  • Alkermes, Inc.$117K
  • Boehringer Ingelheim International GmbH$91K
  • Biogen$57K
  • Teva Pharmaceuticals USA, Inc.$45K
  • E.r. Squibb & Sons, L.L.C.$41K
  • plus $150K from 10 others

What the payments were for

  • Consulting fees$36,21042%
  • Speaking & faculty fees$30,87836%
  • Travel & lodging$15,31118%
  • Food & beverage$4,2915%
  • Education$700%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$705,158 in reported general payments places this provider in the 95th percentile of 1,166 psychiatry providers in Michigan.

See all psychiatry providers in Michigan

Medicare billing

Part B allowed, 2024
$5,846
Medicare patients
41
Services billed
82

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate46$101,441
FanaptIloperidone13$44,774
Abilify MaintenaAripiprazole12$31,625
Risperidone ErRisperidone Microspheres19$13,992
TrintellixVortioxetine Hydrobromide12$5,837
Paliperidone ErPaliperidone31$2,992
Olanzapine48$1,332
Divalproex Sodium ErDivalproex Sodium19$1,304
Buspirone Hcl37$1,268
Desvenlafaxine Succinate ErDesvenlafaxine Succinate12$1,117
Naltrexone Hcl11$582
AmantadineAmantadine Hcl14$573
Aripiprazole25$445
Escitalopram Oxalate24$436
Hydroxyzine Hcl27$348

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$31,716$5,83712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,166 psychiatry providers in Michigan.

Other psychiatry in Grand Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →